ArticleJournal of hepatocellular carcinoma2025
Establishing a Survival Time Prediction Model for Patients with Hepatocellular Carcinoma After TACE Based on CT Radiomics: A Multi-Center Study.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This research constructs a prognostic model for overall survival (OS) in hepatocellular carcinoma (HCC) patients using radiomic features from non-contrast CT scans obtained within 24 hours after transarterial chemoembolization (TACE). Patients and Methods: Patients were retrospectively enrolled from three institutions to form training (n = 112) and validation (n = 56) cohorts from January 2016 to December 2023. All patients underwent a minimum of three TACE treatment sessions. January 2019 served as the cutoff point for dividing the dataset into training and validation cohorts. Univariate and multivariate Cox regression analyses were employed to obtain clinical variables related to OS for constructing the clinical model. The least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses were employed to construct the radiomics model from lipiodol deposits in the target lesions (TL) within 24 hours after the initial TACE, and the clinical-radiomics model was further constructed. Model prediction performance was subsequently assessed by the area under the time-dependent receiver operating characteristic curve (AUC) and calibration curve. Additionally, Kaplan-Meier analysis was used to evaluate the model's value in predicting OS. Results: The clinical-radiomics model predicted OS at 1, 2, and 3 years more accurately than the clinical or radiomics model alone (training group, AUC = 0.787, 0.765 and 0.827, respectively; validation group, AUC = 0.731, 0.713 and 0.798, respectively). The predicted high-risk subgroup based on the clinical-radiomics model had shorter mOS than predicted low-risk subgroup (training group, 16 m vs 37 m, p = 0.0002; validation group 14 m vs 35 m, p<0.0001), enabling risk stratification of various clinical subgroups. Conclusion: The radiomic signature derived from lipiodol within 24 hours post-TACE functions as a prognostic biomarker for OS in HCC patients. The clinical-radiomics model demonstrates robust predictive performance, providing a valuable tool for prognostic evaluation in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.